Literature DB >> 19689374

Development of extracellular signal-regulated kinase inhibitors.

Kimberly Burkhard1, Sarice Smith, Rahul Deshmukh, Alexander D MacKerell, Paul Shapiro.   

Abstract

Activation of the extracellular signal-regulated kinase (ERK) signaling pathway has been implicated in mediating a diverse array of cellular functions including cell differentiation, proliferation, and inflammatory responses. In this review, we will discuss approaches to identify inhibitors of ERK proteins through targeting ATP-dependent and ATP-independent mechanisms. Given the diversity of ERK substrates and the importance of ERK signaling in normal cell functions, emphasis will be placed on the methods for identifying small molecular weight compounds that are substrate selective through ATP-independent interactions and potentially relevant to inflammatory processes. The approach for selective targeting of ERK substrates takes advantage of the basic understanding of unique ERK docking domains that are thought to interact with specific amino acid sequences on substrate proteins. Computer aided drug design (CADD) can facilitate the high throughput screening of millions of compounds with the potential for selective interactions with ERK docking domains and disruption of substrate interactions. As such, the CADD approach significantly reduces the number of compounds that will be evaluated in subsequent biological assays and greatly increases the hit rate of biologically active compounds. The potentially active compounds are evaluated for ERK protein binding using spectroscopic and structural biology methods. Compounds that show ERK interactions are then tested for their ability to inhibit substrate interactions and phosphorylation as well as ERK-dependent functions in whole organism or cell-based assays. Finally, the relevance of substrate-selective ERK inhibitors in the context of inflammatory disease will be discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689374      PMCID: PMC2835149          DOI: 10.2174/156802609789044416

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  101 in total

Review 1.  Protein-protein interfaces: mimics and inhibitors.

Authors:  A G Cochran
Journal:  Curr Opin Chem Biol       Date:  2001-12       Impact factor: 8.822

Review 2.  Structure-based strategies for drug design and discovery.

Authors:  I D Kuntz
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

Review 3.  High throughput screening for protein kinase inhibitors.

Authors:  Holger Wesche; Shou-Hua Xiao; Steve W Young
Journal:  Comb Chem High Throughput Screen       Date:  2005-03       Impact factor: 1.339

Review 4.  Computational identification of inhibitors of protein-protein interactions.

Authors:  Shijun Zhong; Alba T Macias; Alexander D MacKerell
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

5.  Binding response: a descriptor for selecting ligand binding site on protein surfaces.

Authors:  Shijun Zhong; Alexander D MacKerell
Journal:  J Chem Inf Model       Date:  2007-09-27       Impact factor: 4.956

Review 6.  Surface plasmon resonance biosensing.

Authors:  Marek Piliarik; Hana Vaisocherová; Jirí Homola
Journal:  Methods Mol Biol       Date:  2009

Review 7.  Antibody therapy for breast cancer.

Authors:  Amina Willems; Katja Gauger; Cordula Henrichs; Nadia Harbeck
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

8.  The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site.

Authors:  Kari Callaway; Olga Abramczyk; Lance Martin; Kevin N Dalby
Journal:  Biochemistry       Date:  2007-07-21       Impact factor: 3.162

9.  Discovery and characterization of a substrate selective p38alpha inhibitor.

Authors:  Walter Davidson; Lee Frego; Gregory W Peet; Rachel R Kroe; Mark E Labadia; Susan M Lukas; Roger J Snow; Scott Jakes; Christine A Grygon; Christopher Pargellis; Brian G Werneburg
Journal:  Biochemistry       Date:  2004-09-21       Impact factor: 3.162

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  12 in total

1.  Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.

Authors:  Kwan-Young Jung; Ramin Samadani; Jay Chauhan; Kerrick Nevels; Jeremy L Yap; Jun Zhang; Shilpa Worlikar; Maryanna E Lanning; Lijia Chen; Mary Ensey; Sagar Shukla; Rosene Salmo; Geoffrey Heinzl; Caryn Gordon; Troy Dukes; Alexander D MacKerell; Paul Shapiro; Steven Fletcher
Journal:  Org Biomol Chem       Date:  2013-06-14       Impact factor: 3.876

2.  Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity.

Authors:  Nirav G Shah; Mohan E Tulapurkar; Aparna Ramarathnam; Amanda Brophy; Ramon Martinez; Kellie Hom; Theresa Hodges; Ramin Samadani; Ishwar S Singh; Alexander D MacKerell; Paul Shapiro; Jeffrey D Hasday
Journal:  J Immunol       Date:  2017-03-15       Impact factor: 5.422

3.  Importance of domain closure for the autoactivation of ERK2.

Authors:  Daniel Barr; Taiji Oashi; Kimberly Burkhard; Sarah Lucius; Ramin Samadani; Jun Zhang; Paul Shapiro; Alexander D MacKerell; Arjan van der Vaart
Journal:  Biochemistry       Date:  2011-08-25       Impact factor: 3.162

4.  A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.

Authors:  Rachel M Sammons; Nicole A Perry; Yangmei Li; Eun Jeong Cho; Andrea Piserchio; Diana P Zamora-Olivares; Ranajeet Ghose; Tamer S Kaoud; Ginamarie Debevec; Chandra Bartholomeusz; Vsevolod V Gurevich; Tina M Iverson; Marc Giulianotti; Richard A Houghten; Kevin N Dalby
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

5.  Sequence alignment reveals possible MAPK docking motifs on HIV proteins.

Authors:  Perry Evans; Ahmet Sacan; Lyle Ungar; Aydin Tozeren
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

6.  Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells.

Authors:  Borhane Annabi; Eric Vaillancourt-Jean; Alexander G Weil; Richard Béliveau
Journal:  Onco Targets Ther       Date:  2010-11-15       Impact factor: 4.147

7.  Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2.

Authors:  Laurel M Pegram; Jennifer C Liddle; Yao Xiao; Maria Hoh; Johannes Rudolph; Dylan B Iverson; Guy P Vigers; Darin Smith; Hailong Zhang; Weiru Wang; John G Moffat; Natalie G Ahn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-16       Impact factor: 11.205

8.  Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.

Authors:  Sarice R Boston; Rahul Deshmukh; Scott Strome; U Deva Priyakumar; Alexander D MacKerell; Paul Shapiro
Journal:  BMC Cancer       Date:  2011-01-10       Impact factor: 4.430

9.  Effects of ATP-competitive and function-selective ERK inhibitors on airway smooth muscle cell proliferation.

Authors:  Amy E Defnet; Weiliang Huang; Steven Polischak; Santosh Kumar Yadav; Maureen A Kane; Paul Shapiro; Deepak A Deshpande
Journal:  FASEB J       Date:  2019-07-26       Impact factor: 5.834

10.  Peptide Based Inhibitors of Protein Binding to the Mitogen-Activated Protein Kinase Docking Groove.

Authors:  Anita Alexa; Orsolya Ember; Ildikó Szabó; Yousef Mo'ath; Ádám L Póti; Attila Reményi; Zoltán Bánóczi
Journal:  Front Mol Biosci       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.